Topic 8.13 · Patient edition

Pediatrics

Written for patients and families: plain language, same evidence posture. Literature reviewed 2026-09-13.

Plain-language overview

The first thing to understand is that cell and gene therapies for children are not one kind of treatment. Some replace blood-forming cells. Some change a gene in a child's own cells. Others use cells from cord blood or cord tissue. The goal may be to protect or repair injured tissue. A result with one product and one disease does not tell us what another product will do. [1]

For cerebral palsy, pooled studies have found small average gains in gross motor scores after some cord-blood or cord-tissue cell treatments. One large review compared treated children with controls. At six months, the treated group scored 1.36 points higher on a 66-point motor test. At twelve months, it scored 1.42 points higher. Serious adverse events occurred at about the same rate. A second review found a motor benefit for the full group, but results differed between cell products. These findings show a treatment signal. They do not show that every child or every cell product will have the same result. [2-4]

For newborn hypoxic-ischemic encephalopathy, or HIE, cooling remains standard care for eligible babies. A review included four small studies. Babies who also received cord-derived cells were more likely to survive with good development at twelve months. Survival alone did not differ. Only 52 babies received cells, and more than one cell product was used. The size and reach of the benefit remain uncertain. [5]

For autism spectrum disorder, the results are mixed. A 2020 randomized trial enrolled 180 children. One cord-blood infusion did not improve the main outcome or the major secondary outcomes in the full group. A later review found improvement on one rating scale but not another. In 2026, a small randomized trial enrolled 34 children with autism and immune changes. Social responsiveness scores improved after four weekly infusions. That finding applies only to the selected group and short follow-up in that study. [6-8]

Some inherited diseases are different. Hematopoietic stem-cell transplantation can treat certain immune, blood, and metabolic disorders. So can some gene-modified blood-forming cells. Several products are licensed for exact diseases and patient groups. This evidence does not transfer to unlicensed uses of stromal cells or extracellular vesicles. [9,10]

Children in research need added protection. A parent or guardian usually gives permission. A child who can understand should also be asked for assent. Follow-up may need to continue for years. Development, benefit, and some risks can change as a child grows. [11-14]

Cerebral palsy

Researchers hope some cord-blood or cord-tissue cell products may calm harmful inflammation, protect brain cells, support repair, or improve motor function. Products studied have included umbilical cord blood mononuclear cells (UCB-MNCs) and mesenchymal stromal cells (MSCs). These products are not interchangeable. [2-4]

The best recent pooled analysis compared 170 treated children with 171 controls. At six months, the treated group averaged 1.36 points higher on the Gross Motor Function Measure-66 (GMFM-66). At twelve months, the difference was 1.42 points. Serious adverse events were similar. Another pooled analysis found a motor benefit overall. Not every cell-product subgroup had a significant result. Product, dose, route, age, and starting function varied across studies. [2-4]

Figure 1 placeholder — Neurologic outcomes in cerebral palsy and neonatal HIE

Hypoxic-ischemic injury

Hypoxic-ischemic injury happens when tissue gets too little oxygen and blood flow. In a newborn's brain, it can cause hypoxic-ischemic encephalopathy (HIE). Therapeutic hypothermia means controlled cooling. It is standard care for babies who meet the criteria. Four cell studies included 153 babies. Of those, 52 received cord-derived cells. At twelve months, more treated babies were alive and had good development. Survival alone was similar. So were seizures, seizure medicine at discharge, and reported harms. The small treated group and the use of different products limit what we know. [5]

Autism claims

Autism studies have tested whether cord-blood cells can change social or behavior scores. Some studies selected children with signs of immune dysregulation. [6-8]

The largest randomized trial in this group enrolled 180 children. One cord-blood infusion did not improve the main social score or the other major results in the full group. A review of five studies found better scores on one autism scale but not on another. A newer trial enrolled 34 children with autism and immune dysregulation. After four weekly infusions, the treated group had better Social Responsiveness Scale-2 scores at thirteen weeks. The adjusted difference was -6.03 points for the total score and -9.95 points for social cognition. No major harms tied to treatment were reported. The trial has not shown benefit for the wider autism population. [6-8]

Figure 2 placeholder — Why autism findings differ across studies

Genetic diseases

In selected genetic diseases, the goal may be to replace a faulty blood-cell system or give a child's own cells working genetic instructions. These uses are different from investigational stromal-cell or extracellular vesicle (EV) products. [9,10]

For certain genetic diseases, the evidence for cell or gene therapy is much stronger. Hematopoietic stem cells make the body's blood and immune cells. A transplant can replace a faulty blood-forming system. In some monogenic diseases, a lab can add or correct genetic function in a child's own cells. The cells are then returned to the child. The FDA lists licensed cord-blood and gene-modified cell products for defined diseases. These treatments can have major benefits. They also have risks tied to the product and may require a conditioning regimen, such as chemotherapy. [9,10]

Pediatric consent and assent

In covered research with children, parental permission is usually required. A child who can understand should also give assent. This means a clear agreement to take part. The process depends on age, maturity, health, and ability to understand. Families should be told whether the treatment is research or standard care. They should hear what benefit may be possible and what remains unknown. They also need to know the other choices, burdens, and possible costs. [11-13]

A child should not be treated as a bystander in a decision about that child's body. Yet assent is not the same as adult legal consent. The explanation and the child's role should change as the child's developmental capacity changes. [11-13]

Figure 3 placeholder — Pediatric permission, assent, and long-term surveillance

Long-term developmental surveillance

Long-term developmental surveillance means planned follow-up as the child grows. It may track movement, learning, language, behavior, school function, growth, puberty, and fertility. It may also track immune function, organ health, abnormal cell growth, and quality of life. Follow-up should match the product's risks. A lasting gene change raises different questions from a short-lived cell signal. Long follow-up does not mean that harm is expected. A short trial cannot measure every delayed effect or show how long a benefit lasts. [14]

Regulatory status

Regulatory status depends on the exact product, disease, route, country, and date. In the United States, some cord-blood and gene-modified cell products are licensed for certain blood, immune, or genetic diseases. Many uses of cord blood, stromal cells, or EVs for cerebral palsy, HIE, or autism are still being studied. FDA approval for one product does not cover a different product or use. Research status alone does not prove that a treatment works or does not work. [10,15]

Known and theoretical risks

Risks depend on the treatment. They can include infusion reactions, infection, immune reactions, blood clots, and pain or injury from the procedure. They can also include nerve or brain problems and abnormal cell growth. A transplant or gene-modified cell treatment may involve chemotherapy. Other risks may include infertility, organ injury, graft failure, or delayed effects. A product with little short-term harm can still require long follow-up. Ask about the exact product and route, not only the general label stem cells. [2-14]

Standard-care alternatives

Care known to help still matters if a family considers a study. Cerebral palsy needs team-based care and rehab. Eligible babies with HIE need intensive care and cooling. Autism care may include help with development, behavior, school, and health. A genetic disease may need care aimed at that disease, a transplant, or gene therapy. A treatment under study should not replace care already known to help without a clear reason. [2,5,6,9]

Questions to ask

What is my child's exact diagnosis, and what evidence applies to that diagnosis?
What cells or gene-modified product will be used, and how was it made and tested?
Is this established care, an FDA-authorized product for this exact use, or research?
What human studies used the same product, dose, route, age group, and outcome?
What result would be meaningful for my child, and how will it be measured?
What are the short-term risks, delayed risks, and burdens of treatment?
What standard care will continue, and what choices are available if we do not participate?
How will my child be asked for assent, and how will that discussion change with age?
How long will follow-up last, who will provide it, and who pays for it?

Bottom-line evidence statement

Cell and gene therapy for children does not have one answer. Some treatments are established for exact genetic, blood, or immune diseases. In cerebral palsy and HIE, some studies show favorable signals. Products and treatment plans vary, and the evidence is not complete. In autism, controlled results are mixed. They include a large trial with no overall benefit and a small favorable trial in a selected group. The right conclusion depends on the child, disease, product, outcome, and follow-up. [2-15]

Evidence summary

Condition / product	Study design	Main result	Safety	Main limit
Cerebral palsy / cord blood	Pooled patient data; 341 children	GMFM-66 +1.36 at 6 months and +1.42 at 12 months	Similar serious-adverse-event rates	Different patients and protocols [2]
Cerebral palsy / mixed cord products	10 controlled trials	Overall 12-month motor benefit; cell-product subgroups differed	No new pooled safety signal	Products and protocols varied [3]
Newborn HIE / cord-derived cells	4 studies; 153 babies; 52 treated	Favorable development RR 1.89; overall survival not different	Reported events were similar	Small studies; mixed products [5]
Autism / one cord-blood infusion	Randomized Phase II; 180 children	No improvement in main or major secondary outcomes overall	No clear new safety problem	No overall benefit was found [6]
Autism plus immune changes / UCB-MNC	Randomized; 34 children; 13 weeks	SRS-2 total and social-cognition scores favored treatment	No major treatment-related events reported	Small, short, single-center study [8]
Selected genetic diseases / HSCT or gene-modified HSC	Established programs and licensed products	Disease-modifying or potentially curative benefit in defined diseases	Risk depends on product and conditioning	Does not apply to MSCs or EVs [9,10]

Public Evidence Appendix

Download the Public Evidence Appendix (PDF, 7 KB)

Methods and disclosure

Structured Educational Evidence Review per Dr. Mack Sullivan's Master Prompt v1.9 Revision 3E. Topics are literature-reviewed, evidence-graded, and finalised only after explicit author approval.

This library is educational and non-promotional. It does not recommend any specific product, clinic, or procedure, and no patient testimonials or outcome claims are published here.